KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.

@article{Ambrogio2018KRASDI,
  title={KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.},
  author={Chiara Ambrogio and Jens K{\"o}hler and Zhi-Wei Zhou and Haiyun Wang and Raymond M Paranal and Jiaqi Li and Marzia Capelletti and Cristina Caffarra and Shuai Li and Qi Lv and Sudershan R Gondi and J. Craig Hunter and Jia Lu and Roberto Chiarle and David Echarri Santamaria and Kenneth D Westover and Pasi Antero J{\"a}nne},
  journal={Cell},
  year={2018},
  volume={172 4},
  pages={857-868.e15}
}
The mechanism by which the wild-type KRAS allele imparts a growth inhibitory effect to oncogenic KRAS in various cancers, including lung adenocarcinoma (LUAD), is poorly understood. Here, using a genetically inducible model of KRAS loss of heterozygosity (LOH), we show that KRAS dimerization mediates wild-type KRAS-dependent fitness of human and murine KRAS mutant LUAD tumor cells and underlies resistance to MEK inhibition. These effects are abrogated when wild-type KRAS is replaced by… CONTINUE READING

7 Figures & Tables

Connections & Topics

Mentioned Connections BETA
Adenocarcinoma of lung (disorder)Pathogenesis of disease involves geneKRAS gene
The mechanism by which the wild - type KRAS allele imparts a growth inhibitory effect to oncogenic KRAS in various cancers , including lung adenocarcinoma ( LUAD ) , is poorly understood .
The mechanism by which the wild - type KRAS allele imparts a growth inhibitory effect to oncogenic KRAS in various cancers , including lung adenocarcinoma ( LUAD ) , is poorly understood .
All Topics